Paediatric Clinical Trials in the EU: Understanding PIP Requirements

Published on 21/12/2025

Navigating Pediatric Clinical Trials in the EU Through PIP Compliance

Developing medicines for pediatric populations is both a scientific and regulatory challenge. In the European Union (EU), pediatric clinical trials are governed by a structured and mandatory framework known as the Pediatric Investigation Plan (PIP), introduced under Regulation (EC) No 1901/2006. This regulatory mechanism ensures that pharmaceutical development adequately addresses the needs of children without unnecessary delays or ethical compromises. Sponsors wishing to market a medicinal product in the EU must obtain an approved PIP or waiver from the European Medicines Agency (EMA) as part of their development and marketing application strategy.

This article explores the structure, regulatory basis, submission process, and practical considerations of Pediatric Investigation Plans in the EU clinical trial environment. It serves as a guide for sponsors, CROs, and pediatric research institutions aiming to comply with EMA’s pediatric development mandates.

Table of Contents

Background and Regulatory Framework

EU Pediatric Regulation and the Need for PIPs

Before 2007, most drugs used in children were either unlicensed or used off-label, leading to unpredictable safety profiles. To address this gap, the EU adopted the Pediatric Regulation (EC No. 1901/2006 and 1902/2006) mandating that pediatric development be integrated

into the lifecycle of medicinal products.

The regulation introduced:

Mandatory Pediatric Investigation Plans (PIPs)
The Paediatric Committee (PDCO) under the EMA
Incentives such as 6-month SPC extension or 2-year market exclusivity for orphan drugs
The European Network of Paediatric Research at the EMA (Enpr-EMA)

Legal Basis for PIPs

Under Article 7 of Regulation EC No. 1901/2006, any application for a marketing authorization for a new drug, new indication, new dosage form, or new route of administration must be accompanied by an EMA-approved PIP or a waiver.

Core Clinical Trial Insights on PIP Compliance

1. What is a Pediatric Investigation Plan (PIP)?

A PIP is a development plan that outlines how a medicine will be studied in the pediatric population. It includes proposals for:

Quality, non-clinical and clinical studies
Age-appropriate formulations
Timelines for initiation and completion
Waivers or deferrals if applicable

The PIP must be submitted early — typically after pharmacokinetic studies in adults but before confirmatory trials — and must be agreed upon by the Paediatric Committee (PDCO) at EMA.

2. PIP Submission and Evaluation Process

The standard process includes:

Submission through EMA’s secure eSubmission Gateway
PDCO validation (30 days)
Scientific assessment (120 days)
Clock stop for sponsor to respond to PDCO queries (max 90 days)
Final opinion and EMA decision (30 days)

Total approval timeline may range from 8–12 months depending on complexity and completeness of the dossier.

3. Role of the Paediatric Committee (PDCO)

PDCO reviews the PIP for scientific feasibility, ethical considerations, and alignment with pediatric therapeutic needs. The committee may:

Request protocol modifications
Grant waivers (partial or full) if development in children is not appropriate
Allow deferrals for certain studies until after adult data is available

4. Age Stratification and Study Design

Pediatric development must address the needs of all relevant age groups:

Neonates (0–27 days)
Infants (1 month–2 years)
Children (2–11 years)
Adolescents (12–17 years)

Study designs must account for developmental pharmacokinetics, formulations, and ethical acceptability. Adaptive designs and extrapolation from adult data are increasingly accepted when justified.

5. Waivers and Deferrals

Sponsors may request:

Waivers: If the disease does not occur in children or if development is scientifically inappropriate
Deferrals: If pediatric studies would delay adult development and are better conducted later

Requests must be justified and included in the PIP submission.

6. Integration into the Clinical Trial Landscape

Approved PIPs must be implemented in clinical trials that are often registered in EudraCT and must adhere to:

EU CTR 536/2014 and CTIS processes
GCP and ICH E11(R1)
GDPR requirements for data protection

Trial designs must also reflect ethical guidelines such as the Declaration of Helsinki and national ethics committee expectations.

7. Compliance Monitoring and Consequences

Compliance with agreed PIP measures is a prerequisite for marketing authorization. Non-compliance may result in:

Delays in regulatory approvals
Loss of incentives
Regulatory sanctions or additional study requirements

Best Practices & Preventive Measures

Engage early with EMA and PDCO through pre-submission meetings
Use existing pediatric data and models to justify study designs
Plan realistic timelines and resource allocations for pediatric studies
Collaborate with Enpr-EMA for feasibility and recruitment support
Maintain transparent communication with PDCO throughout the lifecycle

Scientific & Regulatory Evidence

Regulation EC No. 1901/2006 and 1902/2006
EMA Procedural Advice on the Evaluation of PIPs
ICH E11(R1) Guideline on Pediatric Drug Development
EMA PDCO Q&A documents
EMA’s annual reports on Pediatric Regulation implementation

Special Considerations

Pediatric studies in rare diseases, oncology, and gene therapy require:

Additional ethical and scientific review layers
Flexible trial designs and extrapolation techniques
Access to pediatric expert networks and advocacy input

Additionally, trials in neonates or in low-resource settings may face infrastructure and training gaps requiring external collaboration.

When Sponsors Should Seek Regulatory Advice

Before initiating first-in-human adult trials — to align pediatric planning
Before filing a waiver or deferral — to avoid rejection
When designing trials involving rare pediatric populations
Prior to submitting PIP modifications
In case of disagreements with PDCO decisions

FAQs

1. When must a PIP be submitted?

Before the start of Phase 3 trials or earlier if seeking accelerated approvals or orphan designations.

2. Can I get a waiver for all age groups?

Yes, but only if justified based on epidemiology, scientific rationale, or safety concerns. PDCO will evaluate each waiver request individually.

3. Is a PIP required for generics?

No. PIPs are generally not required for generic or biosimilar applications unless a new indication or dosage form is introduced.

4. What happens if I change the pediatric study design?

You must submit a modification to your PIP for PDCO review and approval. Failure to update may lead to non-compliance findings.

5. Do all pediatric trials need to be conducted in the EU?

No. Global studies are acceptable as long as they meet EMA and ICH standards and are included in the agreed PIP.

6. What incentives exist for completing a PIP?

Six-month extension of the Supplementary Protection Certificate (SPC) or two years of additional orphan market exclusivity.

Conclusion

Pediatric Investigation Plans are a cornerstone of ethical and effective pediatric clinical development in the European Union. Understanding their structure, submission process, and compliance obligations is essential for sponsors aiming to bring safe and effective treatments to children. Through proactive planning, scientific rigor, and strategic engagement with EMA and PDCO, sponsors can successfully navigate the PIP framework and contribute to closing the therapeutic gap in pediatrics across the EU.